Testing for Severe Acute Respiratory Syndrome-Coronavirus 2: Challenges in Getting Good Specimens, Choosing the Right Test, and Interpreting the Results

Yuan-Po Tu, Timothy J O'Leary, Yuan-Po Tu, Timothy J O'Leary

Abstract

Objectives: We explore ways to reduce errors in laboratory diagnosis of severe acute respiratory syndrome-coronavirus 2 infection by considering preanalytic, analytic, and postanalytic sources. To address preanalytic challenges, we first consider alternative anatomic sites for specimen collection, then discuss self-collection, alternative sampling devices, and transport media. Strengths and limitations of various analytic test systems are considered in the context of postanalytic challenges associated with making test results meaningful, specifically considering the complex relationship between "positive" test results and reproduction and shedding of intact virus. Finally, we provide recommendations regarding healthcare worker surveillance and release of patients with coronavirus disease 2019 from isolation.

Data sources: Material was derived from a Webinar available to the public, manufacturer's websites, U.S. Food and Drug Administration, and Centers for Disease Control and Prevention websites and from both peer-reviewed papers identified by PubMed search and nonpeer-reviewed papers posted on Biorxiv and Medrxiv. Unpublished data came from the Washington State Department of Health.

Study selection: We included studies that compared diagnostic performance strategies without introducing bias due to use of an imperfect gold standard. Case series and case reports were included as necessary to illuminate the significance of results.

Data extraction: Data were extracted manually.

Data synthesis: Sensitivity, specificity, and CIs were computed from article data using a composite reference standard. Nucleic acid-based tests were assumed to perform at 100% specificity.

Conclusions: Although sputum and bronchoalveolar lavage samples provide the highest diagnostic sensitivity for severe acute respiratory syndrome-coronavirus 2, nasopharyngeal, mid turbinate, and nasal specimens are suitable in most cases and require less use of personal protective equipment. When desired sampling materials are unavailable, alternatives may be substituted with no loss of performance. Both reverse transcriptase polymerase chain reaction tests and rapid nucleic acid-based tests offer good performance in most circumstances. Testing is not required to release most patients from isolation.

References

    1. Motley MP, Bennett-Guerrero E, Fries BC, et al. Review of viral testing (polymerase chain reaction) and antibody/serology testing for severe acute respiratory syndrome-coronavirus-2 for the intensivist. Crit Care Explor 2020; 2:e0154.
    1. Zehnbauer BA, Buchman TG. Precision diagnosis is a team sport. J Mol Diagn 2016; 18:1–2
    1. Ai T, Yang Z, Hou H, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: A report of 1014 cases. Radiology 2020; 296:E32–E40
    1. Xiao AT, Tong YX, Zhang S. Profile of RT-PCR for SARS-CoV-2: A preliminary study from 56 COVID-19 patients. Clin Infect Dis. 2020;ciaa460
    1. Xiao AT, Tong YX, Gao C, et al. Dynamic profile of RT-PCR findings from 301 COVID-19 patients in Wuhan, China: A descriptive study. J Clin Virol 2020; 127:104346.
    1. Long DR, Gombar S, Hogan CA, et al. Occurrence and timing of subsequent SARS-CoV-2 RT-PCR positivity among initially negative patients. Clin Infect Dis. 2020:ciaa722
    1. Baughman AL, Bisgard KM, Cortese MM, et al. Utility of composite reference standards and latent class analysis in evaluating the clinical accuracy of diagnostic tests for pertussis. Clin Vaccine Immunol 2008; 15:106–114
    1. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA 2020; 323:1843–1844
    1. Kucirka LM, Lauer SA, Laeyendecker O, et al. Variation in false-negative rate of reverse transcriptase polymerase chain reaction–based SARS-CoV-2 tests by time since exposure. Ann Intern Med. 2020 May 13 [online ahead of print]
    1. Wölfel R, Corman VM, Guggemos W, et al. Virological assessment of hospitalized patients with COVID-2019. Nature 2020; 581:465–469
    1. Sethuraman N, Jeremiah SS, Ryo A. Interpreting diagnostic tests for SARS-CoV-2. JAMA 2020; 323:2249–2251
    1. Centers for Disease Control and Prevention (CDC): Symptom-Based Strategy to Discontinue Isolation for Persons With COVID-19, 2020. Available at: . Accessed August 9, 2020
    1. Yong G, Yi Y, Tuantuan L, et al. Evaluation of the auxiliary diagnostic value of antibody assays for the detection of novel coronavirus (SARS-CoV-2). J Med Virol. 2020 Apr 22. [online ahead of print]
    1. Yang Y, Yang M, Shen C, et al. Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections. medRxiv. 2020.02.11.20021493
    1. Tan W, Lu Y, Zhang J, et al. Viral kinetics and antibody responses in patients with COVID-19. medRxiv
    1. Lin C, Xiang J, Yan M, et al. Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus (SARS-Cov-2)-infected pneumonia (COVID-19). Clin Chem Lab Med 2020; 58:1089–1094
    1. Yu F, Yan L, Wang N, et al. Quantitative detection and viral load analysis of SARS-CoV-2 in infected patients. Clin Infect Dis 2020; 71:793–798
    1. Wu J, Liu J, Li S, et al. Detection and analysis of nucleic acid in various biological samples of COVID-19 patients. Travel Med Infect Dis. 2020;101673
    1. U.S. Department of Health and Human Services Centers for Disease Control and Prevention: Nasopharyneal Sampling, 2020. Available at: . Accessed August 7, 2020
    1. Marty FM, Chen K, Verrill KA. How to obtain a nasopharyngeal swab specimen 2020; 382:e76. . N Engl J Med
    1. YouTube: How to Collect a Specimen to Test for Covid-19, 2020. Available at: . Accessed August 7, 2020
    1. Wyllie AL, Fournier J, Casanovas-Massana A, et al. medRxiv
    1. Piras A, Rizzo D, Uzzau S, et al. Inappropriate nasopharyngeal sampling for SARS-CoV-2 detection is a relevant cause of false-negative reports. Otolaryngol Head Neck Surg. 2020
    1. Van Wesenbeeck L, Meeuws H, D’Haese D, et al. Sampling variability between two mid-turbinate swabs of the same patient has implications for influenza viral load monitoring. Virol J 2014; 11:233.
    1. Fang Z, Zhang Y, Hang C, et al. Comparisons of viral shedding time of SARS-CoV-2 of different samples in ICU and non-ICU patients. J Infect 2020; 81:147–178
    1. Pasomsub E, Watcharananan SP, Boonyawat K, et al. Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease-2019 (COVID-19): A cross-sectional study. Clin Microbiol Infect. 2020 May 15. [online ahead of print]
    1. Kojima N, Turner F, Slepnev V, et al. Self-collected oral fluid and nasal swabs demonstrate comparable sensitivity to clinician collected nasopharyngeal swabs for Covid-19 detection. medRxiv
    1. Tu YP, Jennings R, Hart B, et al. Swabs collected by patients or health care workers for SARS-CoV-2 testing. N Engl J Med 2020; 383:494–496
    1. Wehrhahn MC, Robson J, Brown S, et al. Self-collection: An appropriate alternative during the SARS-CoV-2 pandemic. J Clin Virol 2020; 128:104417.
    1. Péré H, Podglajen I, Wack M, et al. Nasal swab sampling for SARS-CoV-2: A convenient alternative in time of nasopharyngeal swab shortage. J Clin Microbiol 2020; 58:e00721-20.
    1. McCormick-Baw C, Morgan K, Gaffney D, et al. Saliva as an alternate specimen source for detection of SARS-CoV-2 in symptomatic patients using cepheid xpert xpress SARS-CoV-2. J Clin Microbiol 2020; 58:e01109-20.
    1. Berenger BM, Fonseca K, Schneider AR, et al. Sensitivity of nasopharyngeal, nasal and throat swab for the detection of SARS-CoV-2. medRxiv. 2020.05.05.20084889
    1. Hogan CA, Stevens B, Sahoo MK, et al. High frequency of SARSCoV-2 RNAemia and association with severe disease. medRxiv
    1. Andersson M, Carcamo CVA, Auckland K, et al. SARS-CoV-2 RNA detected in blood samples from patients with COVID-19 is not associated with infectious virus. medRxiv
    1. Paoli D, Pallotti F, Colangelo S, et al. Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive naso-pharyngeal swab. J Endocrinol Invest 2020. April 23. [online ahead of print]
    1. Al Saiegh F, Ghosh R, Leibold A, et al. Status of SARS-CoV-2 in cerebrospinal fluid of patients with COVID-19 and stroke. J Neurol Neurosurg Psychiatry 2020; 91:846–848
    1. Wu Y, Guo C, Tang L, et al. Prolonged presence of SARS-CoV-2 viral RNA in faecal samples. Lancet Gastroenterol Hepatol 2020; 5:434–435
    1. Wei XS, Wang X, Niu YR, et al. Diarrhea is associated with prolonged symptoms and viral carriage in corona virus disease 2019. Clin Gastroenterol Hepatol 2020; 18:1753–1759.e2
    1. Xie C, Jiang L, Huang G, et al. Comparison of different samples for 2019 novel coronavirus detection by nucleic acid amplification tests. Int J Infect Dis 2020; 93:264–267
    1. Lo IL, Lio CF, Cheong HH, et al. Evaluation of SARS-CoV-2 RNA shedding in clinical specimens and clinical characteristics of 10 patients with COVID-19 in Macau. Int J Biol Sci 2020; 16:1698–1707
    1. Xing YH, Ni W, Wu Q, et al. Prolonged viral shedding in feces of pediatric patients with coronavirus disease 2019. J Microbiol Immunol Infect 2020; 53:473–480
    1. Callahan CJ, Lee R, Zulauf KE, et al. Open development and clinical validation of multiple 3D-printed nasopharyngeal collection swabs: Rapid resolution of a critical COVID-19 testing bottleneck. J Clin Microbiol 2020; 58:e00876-20.
    1. Cox JL, Koepsell SA. 3D-printing to address COVID-19 testing supply shortages. Lab Med 2020; 51:e45–e46
    1. GitHub - rarnaout/Covidswab: New Home of the Covid19-NP-Swab NP-Swab Manufacturing Project, 2020. Available at: . Accessed August 7, 2020
    1. Cloud JL, Hymas W, Carroll KC. Impact of nasopharyngeal swab types on detection of Bordetella pertussis by PCR and culture. J Clin Microbiol 2002; 40:3838–3840
    1. Rodino KG, Espy MJ, Buckwalter SP, et al. Evaluation of saline, phosphate-buffered saline, and minimum essential medium as potential alternatives to viral transport media for SARS-CoV-2 testing. 2020; 58:e00590-20
    1. Radbel J, Jagpal S, Roy J, et al. Detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is comparable in clinical samples preserved in saline or viral transport medium. J Mol Diagn 2020; 22:871–875
    1. Hart B, Tu YP, Phd RJ, et al. A comparison of health care worker-collected foam and polyester nasal swabs in convalescent COVID-19 patients. medRxiv. 2020.04.28.20083055
    1. Abbott Diagnostics Scarborough: ID NOW COVID-19 Quick Reference Instructions, 2020. Available at: . Accessed August 7, 2020
    1. Vogels CBF, Brito AF, Wyllie AL, et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT–qPCR primer–probe sets. Nat Microbiol. 2020
    1. Lieberman JA, Pepper G, Naccache SN, et al. Comparison of commercially available and laboratory developed assays for in vitro detection of SARS-CoV-2 in clinical laboratories. J Clin Microbiol 2020; 58:e00821-20.
    1. Nalla AK, Casto AM, Huang MLW, et al. Comparative performance of SARS-CoV-2 detection assays using seven different primer/probe sets and one assay kit. J Clin Microbiol 2020; 58:e00557-20.
    1. Brown JR, Atkinson L, Shah D, et al. Validation of an extraction-free RT-PCR protocol for detection of SARS-CoV2 RNA. medRxiv. 2020.04.29.20085910
    1. Smyrlaki I, Ekman M, Lentini A, et al. Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV-2 RT-qPCR. medRxiv
    1. Calvez RM, Taylor A, Calvo-Bado L, et al. Molecular detection of SARS-CoV-2 using a reagent-free approach. medRxiv
    1. Wee SK, Sivalingam SP, Yap EPH. Rapid direct nucleic acid amplification test without RNA extraction for SARS-CoV-2 using a portable PCR thermocycler. Genes (Basel) 2020; 11:664
    1. Wang H, Deng J, Tang YW. Profile of the Alere i Influenza A & B assay: A pioneering molecular point-of-care test. Expert Rev Mol Diagn 2018; 18:403–409
    1. Zhen W, Manji R, Smith E, et al. Comparison of four molecular in vitro diagnostic assays for the detection of SARS-CoV-2 in nasopharyngeal specimens. J Clin Microbiol 2020; 58:e00743-20
    1. Zhen W, Smith E, Manji R, et al. Clinical evaluation of three sample-to-answer platforms for the detection of SARS-CoV-2. J Clin Microbiol 2020; 58:e00783-20.
    1. Basu A, Zinger T, Inglima K, et al. Performance of Abbott ID NOW COVID-19 rapid nucleic acid amplification test in nasopharyngeal swabs transported in viral media and dry nasal swabs, in a New York City academic institution. J Clin Microbiol 2020; 58:e01136-20.
    1. Rhoads DD, Cherian SS, Roman K, et al. Comparison of Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with COVID-19. J Clin Microbiol 2020; 58:e00760-20.
    1. Sherlock Biosciences: Instructions For Use Sherlock TM CRISPR SARS-CoV-2 kit Rx Only for Emergency Use Authorization (EUA) Only, 2020. Available at: . Accessed August 7, 2020
    1. Joung J, Ladha A, Saito M, et al. Point-of-care testing for COVID-19 using SHERLOCK diagnostics. medRxiv
    1. Mori Y, Notomi T. Loop-mediated isothermal amplification (LAMP): A rapid, accurate, and cost-effective diagnostic method for infectious diseases. J Infect Chemother 2009; 15:62–69
    1. Broughton JP, Deng X, Yu G, et al. CRISPR-Cas12-based detection of SARS-CoV-2. Nat Biotechnol 2020; 38:870–874
    1. Gonzalez JM, Shelton JW, Diaz-Vallejo M, et al. Immunological assays for SARS-CoV-2: An analysis of available commercial tests to measure antigen and antibodies. medRxiv. 2020.04.10.20061150
    1. Ng D, Goldgof G, Shy B, et al. SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood from the San Francisco Bay Area. medRxiv
    1. U.S. Food & Drug Administration (FDA): EUA Authorized Serology Test Performance, 2020. Available at: . Accessed August 7, 2020
    1. Whitman JD, Hiatt J, Mowery CT, et al. Test performance evaluation of SARS-CoV-2 serological assays. medRxiv
    1. COVID-19 Testing Project. 2020. Available at: . Accessed August 7, 2020
    1. U.S. Food & Drug Administration (FDA): FAQs on Testing for SARS-CoV-2, 2020. Available at: . Accessed August 7, 2020
    1. Bendavid E, Mulaney B, Sood N, et al. COVID-19 antibody seroprevalence in Santa Clara County, California. medRxiv
    1. Sood N, Simon P, Ebner P, et al. Seroprevalence of SARS-CoV-2-specific antibodies among adults in Los Angeles County, California, on April 10-11, 2020. JAMA 2020; 323:2425–2427
    1. Bryan A, Pepper G, Wener MH, et al. Performance characteristics of the abbott architect SARS-CoV-2 IgG assay and seroprevalence in Boise, Idaho. J Clin Microbiol 2020; 58:e00941-20.
    1. Ioannidis J. The infection fatality rate of COVID-19 inferred from seroprevalence data. medRxiv. 2020.05.13.20101253
    1. Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), March 2020. Euro Surveill 2020; 25:2000421
    1. Centers for Disease Control and Prevention (CDC): Interim Guidelines for COVID-19 Antibody Testing, 2020. Available at: . Accessed August 7, 2020
    1. Green DA, Zucker J, Westblade LF, et al. Clinical performance of SARS-CoV-2 molecular testing. J Clin Microbiol 2020; 58:e00995-20.
    1. Bullard J, Dust K, Funk D, et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clin Infect Dis. 2020;ciaa638
    1. COVID-19 Investigation Team: Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States. Nat Med 2020; 26:861–868
    1. Tom MR, Mina MJ. To interpret the SARS-CoV-2 test, consider the cycle threshold value. Clin Infect Dis. 2020;ciaa619
    1. KCDC: Findings from Investigation and Analysis of re-Positive Cases | Press Release | News Room, 2020. Available at: . Accessed August 7, 2020
    1. Lowry R. Clinical Calculator 2. 2020 Available at: . Accessed August 7, 2020.
    1. Tong ZD, Tang A, Li KF, et al. Potential presymptomatic transmission of SARS-CoV-2, Zhejiang Province, China, 2020. Emerg Infect Dis 2020; 26:1052–1054
    1. Ye F, Xu S, Rong Z, et al. Delivery of infection from asymptomatic carriers of COVID-19 in a familial cluster. Int J Infect Dis 2020; 94:133–138
    1. Sakurai A, Sasaki T, Kato S, et al. Natural history of asymptomatic SARS-CoV-2 infection. N Engl J Med. 2020 Jun 12. [online ahead of print]
    1. Black JRM, Bailey C, Przewrocka J, et al. COVID-19: The case for health-care worker screening to prevent hospital transmission. Lancet 2020; 395:1418–1420
    1. Vahidy FS, Bernard DW, Boom ML, et al. Prevalence of SARS-CoV-2 infection among asymptomatic health care workers in the Greater Houston, Texas, area. JAMA Netw Open 2020; 3: e2016451.
    1. Mansour M, Leven E, Muellers K, et al. Prevalence of SARS-CoV-2 antibodies among healthcare workers at a tertiary academic hospital in New York City. J Gen Intern Med 2020; 35:2485–2486
    1. Arons MM, Hatfield KM, Reddy SC, et al. Public Health–Seattle and King County and CDC COVID-19 Investigation Team: Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med 2020; 382:2081–2090
    1. Treibel TA, Manisty C, Burton M, et al. COVID-19: PCR screening of asymptomatic health-care workers at London hospital. Lancet 2020; 395:1608–1610
    1. Centers for Disease Control and Prevention (CDC): Interim U.S. Guidance for Risk Assessment and Work Restrictions for Healthcare Personnel With Potential Exposure to COVID-19, 2020. Available at: . Accessed August 7, 2020
    1. Gandhi M, Yokoe DS, Havlir DV. Asymptomatic transmission, the achilles’ heel of current strategies to control Covid-19. N Engl J Med 2020; 382:2158–2160
    1. Lee S, Kim T, Lee E, et al. Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea. JAMA Intern Med. 2020 August 6 [online ahead of print]
    1. Chin ET, Lo NC, Huynh BQ, et al. Frequency of routine testing for SARS-CoV-2 to reduce transmission among workers. medRxiv. 2020.05.29.20116731.

Source: PubMed

3
Tilaa